CR20220644A - Derivados de sulfona - Google Patents

Derivados de sulfona

Info

Publication number
CR20220644A
CR20220644A CR20220644A CR20220644A CR20220644A CR 20220644 A CR20220644 A CR 20220644A CR 20220644 A CR20220644 A CR 20220644A CR 20220644 A CR20220644 A CR 20220644A CR 20220644 A CR20220644 A CR 20220644A
Authority
CR
Costa Rica
Prior art keywords
sup
sulfone derivatives
formula
present
compounds
Prior art date
Application number
CR20220644A
Other languages
English (en)
Inventor
Andrew Simon Bell
Hoorn Willem Paul Van
Andreas Kuglstatter
Jérémy BESNARD
Anthony Richard Bradley
Luke Green
Claus Riemer
Buelent Kocer
Wolfgang Haap
Patrizio Mattei
Xavier Lucas
Dmitry Mazunin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220644A publication Critical patent/CR20220644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula I en donde X1 , X2 , X3 , X4 , R1 , R1a, R1b, R2’, R2”, R3’, R3”, R6 y R7 son como se describe en la presente descripción, así como también sus sales aceptables desde el punto de vista farmacéutico. Además, la presente invención se refiere a la fabricación de compuestos de Fórmula I, composiciones farmacéuticas que los comprenden y su uso como medicamentos.
CR20220644A 2020-06-22 2021-06-21 Derivados de sulfona CR20220644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181363 2020-06-22
PCT/EP2021/066767 WO2021259831A1 (en) 2020-06-22 2021-06-21 Sulfone derivatives

Publications (1)

Publication Number Publication Date
CR20220644A true CR20220644A (es) 2023-02-17

Family

ID=71120071

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220644A CR20220644A (es) 2020-06-22 2021-06-21 Derivados de sulfona

Country Status (18)

Country Link
US (1) US20230219953A1 (es)
EP (1) EP4168392A1 (es)
JP (1) JP2023531020A (es)
KR (1) KR20230026479A (es)
CN (1) CN115916756A (es)
AR (1) AR122705A1 (es)
AU (1) AU2021294933A1 (es)
BR (1) BR112022026105A2 (es)
CA (1) CA3187145A1 (es)
CL (1) CL2022003677A1 (es)
CO (1) CO2023000117A2 (es)
CR (1) CR20220644A (es)
IL (1) IL298824A (es)
MX (1) MX2022016455A (es)
PE (1) PE20230838A1 (es)
TW (1) TWI812966B (es)
WO (1) WO2021259831A1 (es)
ZA (1) ZA202213430B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520749A (ja) * 2004-11-23 2008-06-19 レディ ユーエス セラピューティックス， インコーポレイテッド 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
AU2010224693B2 (en) 2009-03-19 2016-07-28 Lifearc Compounds
RU2551847C2 (ru) 2009-12-04 2015-05-27 Тайсо Фармасьютикал Ко., Лтд. Производные 2-пиридона
JP2013525476A (ja) 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
MX2012013465A (es) 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
EP2693880A1 (en) 2011-04-04 2014-02-12 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
AU2012302011A1 (en) 2011-08-29 2014-03-13 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
US9434743B2 (en) * 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
PE20150966A1 (es) 2012-11-08 2015-06-21 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
US20160096850A9 (en) 2013-08-22 2016-04-07 Genentech, Inc. Alkynyl alcohols and methods of use
US10590086B2 (en) * 2014-11-03 2020-03-17 Iomet Pharma Ltd. Pharmaceutical compound
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
CN113166078A (zh) * 2018-12-10 2021-07-23 伊迪亚生物科学有限公司 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂

Also Published As

Publication number Publication date
CO2023000117A2 (es) 2023-04-27
CL2022003677A1 (es) 2023-07-28
WO2021259831A1 (en) 2021-12-30
US20230219953A1 (en) 2023-07-13
TW202208361A (zh) 2022-03-01
EP4168392A1 (en) 2023-04-26
CA3187145A1 (en) 2021-12-30
MX2022016455A (es) 2023-02-01
TWI812966B (zh) 2023-08-21
ZA202213430B (en) 2023-08-30
PE20230838A1 (es) 2023-05-19
AR122705A1 (es) 2022-09-28
CN115916756A (zh) 2023-04-04
AU2021294933A1 (en) 2023-02-02
JP2023531020A (ja) 2023-07-20
IL298824A (en) 2023-02-01
BR112022026105A2 (pt) 2023-01-17
KR20230026479A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
MX2022015886A (es) Derivados de amidopirimidona.
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
EP4299135A3 (en) Benzisoxazole sulfonamide derivatives
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
MX2022009524A (es) Agonistas heterociclicos de glp-1.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
TNSN03110A1 (en) Azaindoles.
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
SE0202462D0 (sv) Novel use
SE0202429D0 (sv) Novel Compounds
MX2023014620A (es) Nuevos profarmacos y conjugados de dimetiltriptamina.
NO20071321L (no) Anti-inflammatoriske midler
MX2022016263A (es) Derivados de ciclobutil-urea.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2022012898A (es) Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
MX2022016455A (es) Derivados de sulfona.
MX2023008562A (es) Derivados de pirazolamida.
CR20210284A (es) Pirazoles como modulares de hemoglobina
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2023006176A (es) Nuevos derivados de indazol acetileno.
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.